Description
Retatrutide 30mg Specifications
- Compound: Retatrutide (LY3437943)
- Class: GLP-1 / GIP / Glucagon triple receptor agonist peptide
- Molecular Formula: C221H343N51O64
- Molecular Weight: 4731.43 g/mol
- CAS Number: 2381089-83-2
- Purity: ≥99% (HPLC tested)
- Physical Form: Lyophilized white powder
- Quantity: 30mg per vial
Research Context
Retatrutide is a synthetic triple-agonist peptide that binds GLP-1, GIP, and glucagon receptors. It is studied in laboratory research investigating incretin pathway signaling, energy-metabolism markers, and triple-receptor co-activation dynamics in non-human models. This 30mg vial supports extended dose-response panels and multi-week in vitro stability studies.
Reconstitution & Storage
Reconstitute with bacteriostatic water and store at 2–8°C. Use within 30 days after reconstitution. Store the sealed lyophilized vial at 2–8°C and avoid repeated freeze-thaw cycles. See our Peptide Reconstitution Guide for detailed procedure.
Purity & Lab Reports
Retatrutide 30mg is tested by HPLC at ≥99% purity. Each batch ships with a Certificate of Analysis accessible via the COA Archive. For background on interpreting peptide purity data, see Understanding Peptide Purity & the Certificate of Analysis.
Related Research Peptides
- Retatrutide 20mg — lower-dose vial in the same series
- Tirzepatide 30mg — dual GLP-1/GIP agonist for comparative research
- Semaglutide 10mg — single GLP-1 receptor agonist for receptor selectivity studies
FOR RESEARCH USE ONLY. Not for human consumption, veterinary, diagnostic, or therapeutic use. Retatrutide 30mg is not approved by the FDA for use in humans.
Reviews
There are no reviews yet.